Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 967585, 7 pages
http://dx.doi.org/10.1155/2014/967585
Clinical Study

Prospective Evaluation of Whole Genome MicroRNA Expression Profiling in Childhood Acute Lymphoblastic Leukemia

1Department of Pediatrics, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
2Department of Medical Genetics, Faculty of Medicine, Ege University, Bornova, 35100 Izmir, Turkey
3Department of Medical Biology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
4Department of Pediatric Hematology, Behcet Uz Children's Hospital, 35210 Izmir, Turkey
5Department of Pediatrics, Faculty of Medicine, Dokuz Eylul University, 35340 Izmir, Turkey

Received 26 February 2014; Revised 7 April 2014; Accepted 22 April 2014; Published 14 May 2014

Academic Editor: Elisa Giovannetti

Copyright © 2014 Muhterem Duyu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Dysregulation of microRNA (miRNA) expression contributes to the pathogenesis of several clinical conditions. The aim of this study is to evaluate the associations between miRNAs and childhood acute lymphoblastic leukemia (ALL) to discover their role in the course of the disease. Forty-three children with ALL and 14 age-matched healthy controls were included in the study. MicroRNA microarray expression profiling was used for peripheral blood and bone marrow samples. Aberrant miRNA expressions associated with the diagnosis and outcome were prospectively evaluated. Confirmation analysis was performed by real time RT-PCR. miR-128, miR-146a, miR-155, miR-181a, and miR-195 were significantly dysregulated in ALL patients at day 0. Following a six-month treatment period, the change in miRNA levels was determined by real time RT-PCR and expression of miR-146a, miR-155, miR-181a, and miR-195 significantly decreased. To conclude, these miRNAs not only may be used as biomarkers in diagnosis of ALL and monitoring the disease but also provide new insights into the potential roles of them in leukemogenesis.